2018 American Transplant Congress
Hispanics' Perceptions of Shared Decision Making in the Transplant Context: A Mixed Methods Study
1Northwestern University, Chicago, IL; 2Baylor University Medical Center, Dallas, TX.
Background: Shared decision making (SDM) has been advocated by health researchers and policy-makers as a model to provide patient-centered care and increase patient knowledge, satisfaction,…2018 American Transplant Congress
Mayo Clinic's First Face Transplant: 17 Months On
Mayo Clinic established a reconstructive transplant program as an extension of clinical practice in 2010. A 31-year-old Caucasian male had significant functional limitations and disfigurement…2018 American Transplant Congress
Regulatory Dendritic Cell (DCreg) Cell Infusion in Living Donor Liver Transplantation
Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Purpose: We have embarked on a first-in-human phase I/II safety and preliminary efficacy trial of donor-derived regulatory dendritic cells (DCreg) in living donor liver transplantation…2018 American Transplant Congress
Intravenous Immunoglobulins and Methylprednisolone Stabilizes Renal Allograft Function in the Majority of Patients with C-aABMR
Erasmus Medical Center, Rotterdam, Netherlands.
BackgroundChronic active antibody mediated rejection (c-aABMR) leads to progressive decline in allograft function and is a major contributor to long-term kidney allograft loss. To date,…2018 American Transplant Congress
Alemtuzumab Induction as a Mediator of Nonadherence in Renal Transplantation
University of Toledo College of Medicine, Toledo, OH.
Introduction: “Non-adherent” (NA) is defined as chronic follow-up absenteeism or medication nonadherence. We aimed to determine whether the single-dosing schedule of Alemtuzumab (Ale) may limit…2018 American Transplant Congress
Excellent Long-Term Outcomes with Kidney Transplants from Deceased Donors with Acute Kidney Injury
Medicine, Columbia University Medical Center, New York, NY.
Kidney transplants (KT) from donors with acute kidney injury (AKI; terminal creatinine ≥ 2.0) are increasingly performed and have similar short-term outcomes compared with KT…2018 American Transplant Congress
Once-Daily MeltDose Tacrolimus Formulation and Renal Function in Caucasian Fast Tacrolimus Metabolizers: Does Early Identification Have an Impact in PK Sensitive Patients?
Tacrolimus (TAC) nephrotoxicity can be seen even at low blood trough levels, with factors beyond trough levels potentially contributing. TAC fast metabolizers have higher Cmax,…2018 American Transplant Congress
Long-Term Efficacy and Safety of Everolimus Based Immunosuppression on De Novo Kidney Transplantation with 9 Years Follow-Up
Purpose: Long-term efficacy and safety of everolimus (EVR) based immunosuppression for de novo kidney transplant recipient who were involved in A1202 study was evaluated in…2018 American Transplant Congress
Effect and Reasons of Rescue Switch to Belatacept among 73 Calcineurin-Inhibitors Treated Kidney Allograft Recipients – A Three Years Retrospective Cohort, Single Center Study
IntroductionAfter kidney transplantation, long-term immunosuppression with calcineurin inhibitors (CNIs) or mTOR inhibitors (mTORi) leads to adverse effects, such as nephrotoxicity and proteinuria. Currently, available data…2018 American Transplant Congress
Prolonged-Release Tacrolimus Dosing in De Novo Kidney Transplantation: Randomized, Open-Label, Pilot Study
A multicenter, randomized, open-label, parallel-group, pilot, 52-wk study in Asian countries that assessed renal function, efficacy, and safety of low vs standard-dose prolonged-release tacrolimus (PRT)…
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 211
- Next Page »